This is a prospective, randomized, open label, parallel-group, multicenter phase III study to
evaluate the efficacy and safety of active specific immunotherapy with racotumomab plus best
supportive care versus best supportive care in patients with advanced NSCLC who have achieved
an Objective Response (Partial or Complete Response) or Stable Disease with standard
first-line treatment. Also immunological parameters will be evaluated. Best supportive
therapy will be administered to all patients in the study according to institutional
standards and includes any subsequent onco-specific therapies. 1082 patients will be included
in the study, with non-small cell lung cancer in stages IIIA (non-resectable), IIIB or IV.